Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Viral Infections

Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model

Bone Marrow Transplantation volume 29, pages 117–120 (2002)Cite this article

Abstract

Respiratory syncytial virus (RSV) is widely recognized as a leading cause of pneumonia, with substantial mortality, in bone marrow transplant recipients. We tested the efficacy of a systemic monoclonal antibody (MAB) preparation possessing a high titer of anti-RSV neutralizing antibody, palivizumab (Synagis) for prophylaxis and therapy of RSV infection in cytoxan (CY) immunosuppressed cotton rats, a model in which the efficacy of a polyclonal anti-RSV product (Respigam) has been demonstrated. Both prophylaxis and therapy with this MAB were highly effective in reducing pulmonary viral replication. However, multiple sequential therapeutic doses of MAB were necessary to control rebound viral replication in continually suppressed animals.

Bone Marrow Transplantation (2002) 29, 117–120. doi:10.1038/sj.bmt.1703326

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Whimbey E, Englund JA, Couch RB . Community respiratory virus infections in immunocompromised patients with cancer Am J Med 1997 102: 10 18

    Article  CAS  Google Scholar 

  2. Harrington RD, Hooton TM, Hackman RC et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center J Infect Dis 1992 165: 987 993

    Article  CAS  Google Scholar 

  3. Bowden RA . Respiratory virus infections after marrow transplantation: the Fred Hutchinson Cancer Center research experience Am J Med 1997 102: 27 30

    Article  CAS  Google Scholar 

  4. McCarthy AJ, Kingman HM, Taylor GS et al. The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation Bone Marrow Transplant 1999 24: 1315 1322

    Article  CAS  Google Scholar 

  5. Dreizin RS, Vyshnevetskaia LO, Bagdamian EE et al. Study of experimental respiratory syncytial virus infection in cotton rats: virologic and immunofluorescent studies Vopr Virusol 1971 16: 670 676

    CAS  PubMed  Google Scholar 

  6. Ottolini MG, Porter DD, Hemming VG et al. Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model Bone Marrow Transplant 1999 24: 41 45

    Article  CAS  Google Scholar 

  7. Prince GA, Jenson AB, Horswood RL et al. The pathogenesis of respiratory syncytial virus infection in cotton rats Am J Pathol 1978 93: 771 792

    CAS  PubMed  PubMed Central  Google Scholar 

  8. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH Jr . Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation – a compassionate use experience Bone Marrow Transplant 2000 25: 161 165

    Article  CAS  Google Scholar 

  9. Gosh S, Champlin RE, Englund J et al. Respiratory syncytial virus upper respiratory tract illness in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin Bone Marrow Transplant 2000 25: 751 755

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported in part by Grant RO86DM.

Author information

Author notes

  1. MG Ottolini, SR Curtis, A Mathews, SR Ottolini and GA Prince: The opinions or assertions contained herein are those of the author(s) and are not to be construed as official or reflecting the views of the Department of Defense, the United States Air Force, or the Uniformed Services University.

Authors and Affiliations

  1. Department of Pediatrics, F Edward Hébert School of Medicine, The Uniformed Services University of the Health Sciences, Bethesda, MD, USA

    MG Ottolini

  2. Virion Systems Inc., Rockville, MD, USA

    SR Curtis, A Mathews, SR Ottolini & GA Prince

Authors
  1. MG Ottolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. SR Curtis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Mathews
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. SR Ottolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. GA Prince
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ottolini, M., Curtis, S., Mathews, A. et al. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant 29, 117–120 (2002). https://doi.org/10.1038/sj.bmt.1703326

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703326

Keywords

This article is cited by

Search

Advanced search

Quick links